Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Vitiligo, New Treatment and Serum s100B
Official title: Serum s100B in Generalized Vitiligo and Its Relation to Oral Baricitinib, Narrow Band Ultraviolet (B) Therapy
Status: Recruiting now
Description:
vitiligo is an autoimmune depigmenting skin disorder characterized by milky white macules or patches, with 2% worldwide prevalence. Vitiligo has unexpected course that significantly influences on patient's quality of life and self-esteem. Multiple medications have been introduced for vitiligo treatment, in this study we work on one of systemic JAK inhibitors
Phases: Phase 2, Phase 3.
What is being studied: drugs — Baricitinib, oral mini pulse; radiation — Narrow Band UVB Treatment.
Who can take part: ages 10 Years to 75 Years, 50 participants planned.
Enrollment status: the registry has not updated this study since its planned completion date, so its current status is unclear. The study started 02 October 2024 and was due to finish 01 October 2025.
Contact: Eman A Osman, bachelor.
Source: ClinicalTrials.gov, NCT06768840 (https://clinicaltrials.gov/study/NCT06768840).
Start date: October 02, 2024
Completion date: October 01, 2025
Organizer: South Valley University
Contact: Eman A Osman, bachelor
Tel.: +20 1127052748
Email: em.ea01127@gmail.com
Clinical Trial Alerts
Sign up and be the first to know about updates on this trial.
FAQOther Questions
- I have a new job - should I tell colleagues about my vitiligo?
Starting a new job can be both exciting and nerve-wracking, — especially if you’re concerned about stares or questions regarding your skin. Taking a proactive approach can help ...
- Are there any famous people with vitiligo?
Many celebrities have dealt with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career. Here are a few courageous famous peo...
- Who is prone to vitiligo?
Vitiligo can affect anyone, regardless of gender, age, or race. Vitiligo prevalence is between 0.76% and 1.11% of the U.S. population, including around 40% of those with the con...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.